These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36532056)

  • 1. Case report: Brain metastasis necrosis with immune checkpoint inhibitors plus chemotherapy for advanced non-small cell lung cancer.
    Niu L; Li X; Meng L; Zhang Y; Wan X; Jing D; Zhou Q; Zhou R
    Front Immunol; 2022; 13():1064596. PubMed ID: 36532056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases.
    Yang G; Xing L; Sun X
    Front Immunol; 2022; 13():852811. PubMed ID: 35422812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Immune Checkpoint Inhibition vs Chemotherapy in Combination With Radiation Therapy Among Patients With Non-Small Cell Lung Cancer and Brain Metastasis Undergoing Neurosurgical Resection.
    Wasilewski D; Radke J; Xu R; Raspe M; Trelinska-Finger A; Rosenstock T; Poeser P; Schumann E; Lindner J; Heppner F; Kaul D; Suttorp N; Vajkoczy P; Frost N; Onken J
    JAMA Netw Open; 2022 Apr; 5(4):e229553. PubMed ID: 35486401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with brain metastases.
    Yan X; Qu F; Zhou Y
    Lung Cancer; 2023 Oct; 184():107322. PubMed ID: 37611495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rationale and toxicity of combined cranial radiotherapy and immune checkpoint inhibitors in non-small cell lung cancer.
    Chen Y; Zhuang H; Wang J
    Asia Pac J Clin Oncol; 2022 Jun; 18(3):165-170. PubMed ID: 32129944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China.
    Sheng J; Li H; Yu X; Yu S; Chen K; Pan G; Xie M; Li N; Zhou Z; Fan Y
    Thorac Cancer; 2021 Nov; 12(22):3019-3031. PubMed ID: 34596346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases.
    Wei Y; Xu Y; Wang M
    Chin Med J (Engl); 2023 Jul; 136(13):1523-1531. PubMed ID: 37106555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice.
    Zouein J; Haddad FG; Eid R; Kourie HR
    Immunotherapy; 2022 Feb; 14(2):155-167. PubMed ID: 34865502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Zhu KK; Wei JL; Xu YH; Li J; Rao XR; Xu YZ; Xing BY; Zhang SJ; Chen LC; Dong XR; Zhang S; Li ZY; Liu CW; Meng R; Wu G
    Curr Med Sci; 2023 Apr; 43(2):344-359. PubMed ID: 37002471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors plus anlotinib versus anlotinib alone as third-line treatment in advanced non-small-cell lung cancer: a retrospective study.
    Zhang W; Zhang C; Yang S; Chen Q; Wang C; Guo Q
    Future Oncol; 2021 Nov; 17(31):4091-4099. PubMed ID: 34254526
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
    Smit HJM; Aerts J; van den Heuvel M; Hiltermann TJN; Bahce I; Smit EF; Dingemans AC; Hendriks LE; Stigt JA; Schramel FMNH; van Tinteren H; Groen HJM;
    Lung Cancer; 2020 Feb; 140():107-112. PubMed ID: 31911323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer.
    Zhou J; Bao M; Gao G; Cai Y; Wu L; Lei L; Zhao J; Ji X; Huang Y; Su C
    BMC Med; 2022 Jul; 20(1):256. PubMed ID: 35902848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
    Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
    BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application.
    Xiao G; Liu Z; Gao X; Wang H; Peng H; Li J; Yang L; Duan H; Zhou R
    Immunotherapy; 2021 Aug; 13(12):1031-1051. PubMed ID: 34231370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracranial activity of first-line immune checkpoint inhibitors combined with chemotherapy in advanced non-small cell lung cancer.
    Huang Z; Wu F; Xu Q; Song L; Zhang X; Wang Z; Deng L; Zhang Y; Zeng L; Yang N
    Chin Med J (Engl); 2023 Jun; 136(12):1422-1429. PubMed ID: 37195128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of immune checkpoint inhibitors plus anlotinib in small cell lung cancer with brain metastases: a retrospective, multicentre study.
    Zhou S; Ren F; Li C; Jiang L; Meng X; Huang Z
    J Neurooncol; 2022 Dec; 160(3):631-642. PubMed ID: 36346496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations.
    Zullo L; Rossi G; Dellepiane C; Tagliamento M; Alama A; Coco S; Longo L; Pronzato P; Maria A; Genova C
    Immunotherapy; 2021 Apr; 13(6):509-525. PubMed ID: 33626932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
    Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
    Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.